Phase Ib Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Latest Information Update: 22 Jul 2024
At a glance
- Drugs RSV LID deltaM2-2 1030s (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- 07 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 21 Mar 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2024.